Abstract：
UNASSIGNED: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC.
UNASSIGNED: In this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed.
UNASSIGNED: 170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS (p = 0.024) and OS (p = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS (p = 0.016) and OS (p = 0.006), respectively.
UNASSIGNED: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.
UNASSIGNED: In this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed.
UNASSIGNED: 170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS (p = 0.024) and OS (p = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS (p = 0.016) and OS (p = 0.006), respectively.
UNASSIGNED: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.
摘要：
■三阴性乳腺癌（TNBC）的特点是高复发率，特别是在新辅助化疗（NAC）后残留疾病的患者中。卡培他滨被用作残留TNBC的标准辅助治疗。我们旨在调查有关卡培他滨对残留TNBC疗效的真实数据。
■在这项回顾性多中心研究中，对有残留病的TNBC患者进行评价。患者,接受标准蒽环类和基于紫杉烷的NAC和佐剂卡培他滨的患者符合条件.总生存期（OS），分析无病生存率（DFS）和毒性。
■170例有残留病的TNBC患者。其中,62.9%为绝经前。在分析的时候，复发率为30%，死亡率为18%。3年DFS和OS分别为66%和74%，分别。在接受卡培他滨辅助治疗的患者中，残留淋巴结阳性疾病是DFS(p=0.024)和OS(p=0.032)的独立预测因子。进行乳房切除术和T2残留肿瘤的存在是DFS（p=0.016）和OS（p=0.006）的独立预测因子，分别。
■发现卡培他滨的疗效低于以前的研究。选择的患者可以从添加卡培他滨进一步受益。发现与卡培他滨相关的毒性低于预期。
■在这项回顾性多中心研究中，对有残留病的TNBC患者进行评价。患者,接受标准蒽环类和基于紫杉烷的NAC和佐剂卡培他滨的患者符合条件.总生存期（OS），分析无病生存率（DFS）和毒性。
■170例有残留病的TNBC患者。其中,62.9%为绝经前。在分析的时候，复发率为30%，死亡率为18%。3年DFS和OS分别为66%和74%，分别。在接受卡培他滨辅助治疗的患者中，残留淋巴结阳性疾病是DFS(p=0.024)和OS(p=0.032)的独立预测因子。进行乳房切除术和T2残留肿瘤的存在是DFS（p=0.016）和OS（p=0.006）的独立预测因子，分别。
■发现卡培他滨的疗效低于以前的研究。选择的患者可以从添加卡培他滨进一步受益。发现与卡培他滨相关的毒性低于预期。
